Dr. Diana Tichy

Dr. Diana Tichy

Dr. Diana Tichy




+49 6221 42 2261


+49 6221 42 2397


TP 4



Area of Work  

  • Analysis of prospective and retrospective studies, analysis of microarray data, mainly resulting from RNA-sequencing experiments. 
  • A current research project of mine runs in cooperation with partners from the National Tumor Center Heidelberg. We provide a pipeline for the analysis of data resulting from a RNA Immunoprecipitation sequencing experiment performed to identify genome-wide targets of a microRNA.
  • My further research interest focuses on the application of Extreme Value Statistics in the framework of microarray data aiming in the estimation of tail distributions.

Education and Background

  • Department of Biostatistics at the DKFZ since February 2013
  • Dr. rer. nat., Department of Statistics, University of Würzburg, 2012
  • 2007-2012, Scientific staff member, Department of Statistics and University Hospital, University of Würzburg 
  • Diploma in Mathematics, University of Würzburg, 2007

Selected Publications  

  • Groß  J, Nattenmüller J, Hemmer S, Tichy D, Goldschmidt H, Bertsch U, Delorme S, Kauczor  HU, Hillengass J, Merz M:   Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma. Subgroup analysis of the prospective GMMG MM5 trial. Oncotarget 2017, 8(40): 68460-68471.
  • Tichy D, Pickl J, Benner A, Sueltmann H: Experimental design and data analysis of Ago-RIP-Seq experiments for the identification of microRNA targets. Briefings in Bioinformatics} 2017.
  • Wolf MB, Edler C, Tichy D, Röthke MC, Schlemmer HP, Herfarth K, Bonekamp D:  Diffusion-weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique.  Journal of Magnetic Resonance Imaging 2017, 46(3):850-860.
  • Pickl JM, Tichy D, Kuryshev V, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, et al: Ago-RIP-Seq identifies the Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.  Oncotarget 2016, 7(37): 59589-59603.
  • Burth S, Kickingereder P, Eidel P, Tichy D, Bonekamp D, Weberling L, Wick A, Löw S, Hertenstein A, Nowosielski M, Schlemmer HP, Wick W, Bendszus M, Radbruch A: Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.  Neuro Oncology 2016, Vol 18:4.
  • Fellenberg J, Sähr H, Kunz P, Zhao Z, Liu L, Tichy D, Herr I: Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6. Cancer Letters 2016, 371(1): 134-141.
  • Meissner J, Tichy D, Katzke V, Kühn T, Dietrich S, Schmitt T, Ziepert M, Kuhnt E, Rixecker T, Zorn M, Witzens-Harig M, Pfreundschuh M, Ho AD:  Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.  Annals of oncology  2015, 26(8): 1771-1776.
  • Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider A, Fenchel M, Schlemmer HP, Hadaschik B: Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided nbiopsy at 3.0 Tesla.  European Journal of Radiology 2014. 24(2):344-352.




to top